The patent for semaglutide expired in March 2026, and 13 companies have launched 26 generics across different formulations: autoinjectors, vials, and pills, which price is lower than the branded drug.And because the India market was quite under-penetrated for GLP-1, we are seeing affordability driving volume expansion
This level is generally considered effective yet gentle enough to minimize the risk of irritation, especially for sensitive skin types
The best candidates for injection therapy are those looking for targeted health benefits like boosting energy, improving metabolism, supporting fat loss, or enhancing overall wellness
Now look at what the research says actually happens when people get consistent access to GLP-1 medications
doi: 10.1038/s41574-020-0349-5 338 KhantakovaJNMutovinaAAyriyantsKABondarNP
Ipamorelin is not FDA-approved for any indication